Argentina Phenylketonuria Market Size & Outlook, 2026-2034
Argentina Phenylketonuria Market Insights
- As per Reed Intelligence insights, the Argentina Phenylketonuria Market stood at USD 13.5 Million in 2025 and is anticipated to grow to USD 22.9 Million by 2034.
- The Argentina market is expected to advance at a CAGR of 6.09% from 2026 through 2034.
- In 2025, Enzyme Replacement Therapy accounted for the highest share of the By Treatment Type market size.
- During the forecast period, Dietary Therapy is set to register the highest growth, making it the most lucrative By Treatment Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Argentina accounted for 1.02% of the global Phenylketonuria Market size.
- By 2034, United States is expected to lead the global Phenylketonuria Market in terms of market size.
- Within LATAM, Brazil is projected to dominate the regional Phenylketonuria Market size by 2034.
- Mexico is identified as the fastest-growing market in LATAM, anticipated to reach USD 55.43 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 13.5 Million |
| Market Size In 2034 | USD 22.9 Million |
| Largest segment | Enzyme Replacement Therapy |
| Units | Revenue in USD Million |
| CAGR | 6.09% (2026-2034) |
| Segmnetation Covered | |
| By Treatment Type |
|
| By Diagnosis |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Argentina Phenylketonuria Market By Treatment Type 2026-2034 (USD Million)
| By Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzyme Replacement Therapy | XX.x | XX.x | XX.x | 6.65 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gene Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medication | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dietary Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Argentina Phenylketonuria Market By Diagnosis 2026-2034 (USD Million)
| By Diagnosis | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genetic Testing | XX.x | XX.x | XX.x | 7.14 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biochemical Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Newborn Screening | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Argentina Phenylketonuria Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Clinics | XX.x | XX.x | XX.x | 5.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Home Healthcare | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.